Show simple item record

dc.contributor.authorO'Connell, Oisin J
dc.contributor.authorKennedy, Marcus P
dc.contributor.authorHenry, Michael T
dc.date.accessioned2012-04-10T13:15:16Z
dc.date.available2012-04-10T13:15:16Z
dc.date.issued2011-11
dc.identifier.citationIdiopathic pulmonary fibrosis: treatment update. 2011, 28 (11):986-99 Adv Ther
dc.identifier.issn1865-8652
dc.identifier.pmid21975927
dc.identifier.doi10.1007/s12325-011-0066-5
dc.identifier.urihttp://hdl.handle.net/10147/218049
dc.description.abstractIdiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a survival advantage for any agent in the management of patients with IPF. The limited effectiveness of current treatment regimes has led to a search for novel therapies including antifibrotic strategies. This article reviews the evidence supporting the treatments currently used in the management of IPF.
dc.language.isoen
dc.rightsArchived with thanks to Advances in therapyen_GB
dc.subject.meshAnti-Inflammatory Agents
dc.subject.meshAnticoagulants
dc.subject.meshAntioxidants
dc.subject.meshClinical Trials as Topic
dc.subject.meshCombined Modality Therapy
dc.subject.meshDisease Progression
dc.subject.meshHumans
dc.subject.meshIdiopathic Pulmonary Fibrosis
dc.subject.meshImmunosuppressive Agents
dc.subject.meshLung Transplantation
dc.subject.meshMedication Therapy Management
dc.subject.meshOutcome Assessment (Health Care)
dc.subject.meshOxygen Inhalation Therapy
dc.subject.meshPalliative Care
dc.subject.meshReceptors, Endothelin
dc.subject.meshTumor Necrosis Factor-alpha
dc.titleIdiopathic pulmonary fibrosis: treatment update.en_GB
dc.contributor.departmentDepartment of Respiratory Medicine, Cork University Hospital, Wilton, Cork, Ireland.
dc.identifier.journalAdvances in therapy
dc.type.qualificationlevelN/Aen
cr.approval.ethicalN/Aen
dc.description.provinceMunsteren
dc.description.provinceMunster
html.description.abstractIdiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a survival advantage for any agent in the management of patients with IPF. The limited effectiveness of current treatment regimes has led to a search for novel therapies including antifibrotic strategies. This article reviews the evidence supporting the treatments currently used in the management of IPF.


This item appears in the following Collection(s)

Show simple item record